Electro-Optical Sciences: Corporate Presentation Summary Print E-mail
Monday, 23 March 2009 17:37
Since I last wrote about Electro-Optical Sciences (MELA) positive results for MelaFind as a new diagnostic screening device for melanoma, the Company presented at the Cowen and Company Healthcare conference. Below is a summary of the presentation, including the razor/razor blade business model and targeted commercialization plans on a regional basis for MelaFind. The pivotal Phase 3 trial for MelaFind achieved statistically significant results for the pre-specified clinical outcomes agreed upon with the FDA and it is the largest prospective study ever conducted for melanoma screening. MELA expects to file for FDA approval of MelaFind as a new medical device once the final statistical report is prepared and integrated into a PMA filing. The PMA filing will be given a priority, expedited 180-day review and a FDA Advisory Panel meeting is expected to occur around the mid-point of the review cycle.
Read more...
 
Poniard Pharma Restructures to Conserve Cash Print E-mail
Friday, 20 March 2009 09:55
Visit the BioMedReports.com research section to view or download the PDF for Poniard Pharma (PARD) along with other free PDF stock research reports, corporate investor presentations, and fact sheets: http://biomedreports.com/research.html PARD announces minor restructuring. This morning, Poniard announced that the company will further focus its cash resources on the clinical and commercial development of picoplatin, their late-stage oncology candidate. As a result, the company will discontinue all preclinical research activities. To this end, Poniard will release 12 percent of its workforce (eight employees) associated with these activities effective at the end of March 2009.
Read more...
 
King Pharma: A Value Play on New Drug Approvals Print E-mail
Thursday, 19 March 2009 14:07
King Pharma (KG) is a specialty pharmaceutical company which recently acquired Alpharma for $1.6B and has three pending NDAs at the FDA for new drug approvals and received a complete response late last year for Remoxy (an abuse deterrent form of extended-release oxycodone) along with Pain Therapeutics (PTIE). BioMedReports.com FDA and Clinical Trial Calendars 
Read more...
 
Oncothyreon (ONTY) Research Note Print E-mail
Wednesday, 18 March 2009 13:49
Visit the BioMedReports.com research section to view or download the PDF for Oncothyreon (ONTY) along with other free PDF reports and corporate investor presentations:http://biomedreports.com/research.html Oncothyreon: Price: $1.21; Market Cap (MM): $23.6 -- Market Outperform; Target Price: $4.00 
Read more...
 
Cougar Biotech Research Note Print E-mail
Tuesday, 17 March 2009 13:33
Visit the BioMedReports research section to view or download the PDF for Cougar Biotechnology (CGRB) along with other free PDF reports and corporate investor presentations: http://biomedreports.com/research.htmlCGRB: Price: $28.46; Market Cap (MM): $590.1Market Outperform; Target Price: $36.00Simos Simeonidis, Ph.D. - Senior Biotech Analyst, Rodman & RenshawCougar reports '08 earnings: Abiraterone soon in second large Phase III trial
Read more...
 
Synta Pharma Proceeds with Clinical Trial Print E-mail
Tuesday, 17 March 2009 08:50
Visit the BioMedReports.com research section to view or download the PDF for Synta Pharma (SNTA) along with other free PDF reports and presentations: http://biomedreports.com/research.html Synta Pharma: Price: $1.94; Market Cap (MM): $65.8Market Perform; Simos Simeonidis, Ph.D. - Senior Biotech Analyst, Rodman & RenshawSynta moves forward with investment in Phase I/II trial before GSK decision  
Read more...
 
Poniard Pharma Awaits Key Cancer Drug Data Print E-mail
Tuesday, 17 March 2009 08:24
Visit the BioMedReports.com research section to view or download the six page PDF for Poniard Pharma (PARD) along with other free PDF reports and presentations:http://biomedreports.com/research.htmlPARD: Price: $1.87; Market Cap (MM): $64.9Market Outperform; Target Price: $10.00Simos Simeonidis, Ph.D. - Senior Biotech Analyst, Rodman & RenshawKPMG's "going concern" a non-issue should picoplatin work in SPEAR
Read more...
 
Electro-Optical Sciences: Enabling Early Melanoma Detection Print E-mail
By M.E.Garza   
Monday, 16 March 2009 15:03
MELA recently announced positive topline results in a pivotal clinical trial for MelaFind, which was conducted at seven medical centers across the U.S. and included nearly 1,400 patients and over 1,800 pigmented skin lesions. A larger study will also be conducted for MelaFind, with the results planned for submission to the FDA.
Read more...
 
Javelin Pharma: Late-Stage Pipeline Targets Pain Print E-mail
Sunday, 15 March 2009 17:10
Javelin Pharma (JAV) is focused on the late stage clinical development of three Phase 3 compounds while seeking partnerships for a non-dilutive source of funding. In mid-January, JAV established a partnership for Dyloject (injectable diclofenac) with Therabel Pharma to market the drug in Europe, where it is already approved for use. The deal is worth up to $71M (with $12M in upfront cash and $59.5M in sales/regulatory milestones) and extends Javelin's cash resources until early 2010, during which time the Company expects to achieve additional clinical and regulatory milestones in addition to marketing partnerships for its other late-stage compounds in the U.S. market and other regions.
Read more...
 
Cytori Therapeutics: Stock Profile and 2009 Outlook Print E-mail
Saturday, 14 March 2009 18:04
Cytori Therapeutics (CYTX) is a leading global innovator in the emerging field of regenerative medicine using adipose (fat) tissue as a rich source of adult stem cells capable of differentiating into a variety of cell types. The Company develops and markets cell banking, therapeutic, and cosmetic medicine applications for its Celution System, which enables real-time regenerative cell therapy applications by harvesting and processing a small amount of patient-derived fat tissue in about one hour to harvest the adipose-derived stem and regenerative cells (ADRCs).A 17-page PDF stock profile report for Cytori is available to view or download for free at BioMedReports.com in the stock research section: http://biomedreports.com/research.htmlThe accompanying table includes an outline of the expected clinical trial milestones and corporate goals for Cytori in 2009 and is included in the PDF report for easier viewing.Cytori is a commercial-stage regenerative medicine company which is developing the Celution System to process a patient's own fat (adipose) tissue in about one hour for a variety of reconstructive and cosmetic medicine (e.g. breast augmentation) applications, with the latter process consisting of supercharged or enhanced fat grafts to enable long-term retention of the fat graft as a natural alternative to artificial implants for breast reconstruction or augmentation.
Read more...
 
<< Start < Prev 361 362 363 364 365 366 367 368 369 Next > End >>

Page 367 of 369

Newsletter